Top Page
MicroPort CardioFlow Medtech Corp.
(2160)
MicroPort CardioFlow Medtech Corp. (2160) vs. iShares MSCI Hong Kong ETF (EWH)
MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model
MicroPort CardioFlow Medtech Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 367.53M | 361.56M | 336.21M | 251.03M | 200.81M | 103.93M |
| Gross Profit | 253.91M | 251.21M | 229.93M | 162.13M | 118.70M | 45.38M |
| EBITDA | -87.81M | -113.32M | -386.05M | -347.91M | -173.99M | -227.43M |
| Net Income | 4.85M | -49.45M | -471.53M | -454.39M | -183.26M | -398.09M |
Balance Sheet | ||||||
| Total Assets | 2.67B | 2.68B | 2.58B | 3.00B | 3.36B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 1.36B | 1.07B | 2.08B | 2.42B | 612.47M |
| Total Debt | 279.62M | 76.86M | 70.48M | 95.47M | 125.64M | 15.83M |
| Total Liabilities | 450.55M | 454.07M | 242.25M | 247.55M | 265.52M | 1.46B |
| Stockholders Equity | 2.18B | 2.19B | 2.33B | 2.75B | 3.10B | -345.18M |
Cash Flow | ||||||
| Free Cash Flow | -179.62M | -270.06M | -237.50M | -231.60M | -269.94M | -167.97M |
| Operating Cash Flow | -26.82M | -111.67M | -206.99M | -182.53M | -161.50M | -109.75M |
| Investing Cash Flow | -668.17M | -798.50M | -596.06M | -179.78M | -437.48M | -56.42M |
| Financing Cash Flow | -2.75M | -56.31M | -25.61M | -136.42M | 2.23B | 676.42M |
MicroPort CardioFlow Medtech Corp. Technical Analysis
MicroPort CardioFlow Medtech Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$6.72B | 20.99 | 11.24% | 1.26% | 25.18% | 55.79% | |
55 Neutral | HK$9.49B | 21.07 | 8.69% | 1.88% | 14.56% | 61.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$7.64B | 545.45 | 0.22% | ― | -4.38% | ― | |
44 Neutral | HK$279.56M | -1.59 | -29.79% | ― | 6.10% | -115.12% | |
41 Neutral | HK$1.12B | -1.59 | -26.80% | ― | -8.56% | -14.84% | |
39 Underperform | HK$4.43B | -18.06 | -11.20% | ― | 29.25% | 9.02% |
MicroPort CardioFlow Medtech Corp. Corporate Events
MicroPort CardioFlow Medtech Corporation announced the formal release of one-year follow-up data from an early feasibility study of AltaValve, a transcatheter mitral valve replacement device independently developed by its associated company 4C Medical Technologies. The multicenter study in Europe, the U.S. and Japan enrolled 30 high‑surgical‑risk patients with severe symptomatic mitral regurgitation and showed a 97% technical success rate, complete elimination of regurgitation, improved hemodynamics, no cardiogenic deaths, and no major adverse events such as stroke or reintervention, with 96% of patients improving to NYHA Class I or II at one year. AltaValve, the world’s first atrial‑anchored, fully retrievable, low‑profile transseptal TMVR system, has received two FDA Breakthrough Device designations in 2024 and is in pivotal trials in Europe and the U.S., supported by a recent US$175 million Series D financing at 4C Medical. The results and regulatory momentum underscore the potential of AltaValve to strengthen MicroPort CardioFlow’s positioning in the global structural heart market, especially in its exclusive Greater China territories, while the company cautions that ultimate commercialization is not guaranteed.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corporation announced that its VitaFlow series TAVI systems have now been introduced in 35 countries and regions, with cumulative implantations nearing 1,300 cases. The company expects implantation volume in 2025 to exceed 850 procedures, implying a year-on-year increase of almost 350%, and reported that second-half 2025 volumes grew by more than 170% versus the first half, driven by CE-mark-backed expansion of VitaFlow Liberty in Europe and rising adoption in emerging Asian and Latin American markets. Management believes the recent acquisition of MicroPort Cardiac Rhythm Management Limited will bolster local distribution channels and clinical support in mature markets like Europe, improving market access and deepening penetration for its TAVI products; the group plans to leverage these integration synergies to develop next-generation TAVI devices, broaden its structural heart disease solutions, and strengthen competitiveness in global valve therapy.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corporation has completed the acquisition of MicroPort Cardiac Rhythm Management Limited and its subsidiaries, which have now become indirect subsidiaries of the group. The deal, structured as a very substantial acquisition and connected transaction involving the issue of new shares under a specific mandate, significantly reshapes the company’s shareholding structure, with total shares rising from about 2.41 billion to 6.37 billion and diluting existing public shareholders while bringing in the original shareholders of the target company and strengthening the stake held by its major shareholder, MicroPort. The merger expands MicroPort CardioFlow’s business from structural heart interventions into cardiac rhythm management, establishing a diversified platform across the “Total Cardio” field, broadening its global market presence, and enhancing competitiveness and risk resilience as it seeks to integrate technologies and resources to offer comprehensive heart failure management solutions.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the company’s leadership structure, which is crucial for its strategic direction and operational efficiency, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corp. announced that its shareholders approved a merger agreement at an extraordinary general meeting held on December 15, 2025. The merger involves MicroPort CardioFlow CRM Limited and MicroPort Cardiac Rhythm Management Limited, with plans to issue new shares to complete the merger. This strategic move is expected to enhance the company’s market position and expand its product offerings in the cardiovascular sector.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corp. announced significant changes in its board of directors, with the resignation of Mr. Zhao Liang, Ms. Yan Luying, and Mr. Zhang Junjie, effective December 15, 2025. The company expressed gratitude for their contributions and confirmed there were no disagreements with the board. Dr. Brian Chang has been appointed as a non-executive director and co-chairman. Dr. Chang brings a wealth of experience in medical technology and academia, having co-founded startups and served as a lecturer at MIT. His appointment is expected to enhance the company’s strategic direction and innovation in cardiovascular technologies.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corp. has announced significant changes in its board committees and the establishment of new strategic committees to enhance its market positioning. The company aims to leverage its technological capabilities and expertise in cardiovascular devices to enter the heart failure treatment market, following a proposed merger. This strategic move is expected to position the company as a leader in heart failure diagnosis and treatment, offering comprehensive management solutions that integrate device-based therapy and continuous monitoring.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corporation has issued a supplemental announcement to clarify the deadline for lodging share transfers to qualify for voting rights at the upcoming Extraordinary General Meeting (EGM). The corrected deadline is now set for 4:30 p.m. on Tuesday, December 9, 2025, instead of the previously stated date. This clarification ensures stakeholders are accurately informed about the voting process, maintaining transparency and trust in the company’s governance.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
MicroPort CardioFlow Medtech Corp. has announced an extraordinary general meeting to discuss a proposed merger with MicroPort Cardiac Rhythm Management Limited. The merger involves issuing new shares to the target company’s shareholders, which could significantly impact the company’s market position and shareholder value.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.